Advocacy intelligence hub — real-time data for patient organizations
Xatmep: FDA approved
Management of pediatric patients with active polyarticular juvenile idiopathic arthritis (pJIA) who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of first-line therapy including full dose non-steroidal anti-inflammatory agents (NSAIDs).
Actemra: FDA approved
ACTEMRA® (tocilizumab) for subcutaneous injection is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
Actemra
Genentech, Inc.
Xatmep
(methotrexate oral solution)Orphan drugSilvergate Pharmaeuticals, Inc.
Folate Analog Metabolic Inhibitor [EPC]
12.1 Mechanism of Action Methotrexate inhibits dihydrofolic acid reductase. Dihydrofolates must be reduced to tetrahydrofolates by this enzyme before ...
Actemra
(tocilizumab)Orphan drugGenentech, Inc.
Interleukin-6 Receptor Antagonist [EPC]
12.1 Mechanism of Action Tocilizumab binds to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R), and has been shown to inhibit IL-6-m...
Browse all Rheumatoid factor-positive polyarticular juvenile idiopathic arthritis news →
View all Rheumatoid factor-positive polyarticular juvenile idiopathic arthritis specialists →